A prospective pharmacogenetic study of 5FU/LV in high-risk stage II and III colon cancer patients.

被引：0
|
作者：
Mulder, K [1 ]
Scarfe, AG [1 ]
Koski, S [1 ]
Au, HJ [1 ]
Butts, C [1 ]
Fields, A [1 ]
Razavy, H [1 ]
Graham, K [1 ]
Cass, CE [1 ]
Sawyer, MB [1 ]
机构：
[1] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2067
引用
收藏
页码：143S / 143S
页数：1
相关论文
共 50 条
  • [21] Randomized phase III trial comparing 5FU bolus and low dose leucovorin versus 5FU bolus plus continuous 5FU infusion and high dose LV in metastatic colorectal cancer
    Bosset, JF
    DeGrammont, A
    Milan, C
    Rougier, P
    Bouche, O
    Etienne, PL
    Morvan, F
    Louvet, C
    Guillot, T
    Bedenne, L
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 702 - 702
  • [22] Identification of patients with high-risk stage II colon cancer for adjuvant therapy
    Quah, Hak-Mien
    Chou, Joanne F.
    Gonen, Mithat
    Shia, Jinru
    Schrag, Deborah
    Landmann, Ron G.
    Guillem, Jose G.
    Paty, Philip B.
    Temple, Larissa K.
    Wong, W. Douglas
    Weiser, Martin R.
    DISEASES OF THE COLON & RECTUM, 2008, 51 (05) : 503 - 507
  • [23] Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III
    Taal, BG
    Van Tinteren, H
    Zoetmulder, F
    BRITISH JOURNAL OF CANCER, 2001, 85 (10) : 1437 - 1443
  • [24] Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III
    B G Taal
    H Van Tinteren
    F A N Zoetmulder
    British Journal of Cancer, 2001, 85 : 1437 - 1443
  • [25] Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer
    Moretto, Roberto
    Falcone, Alfredo
    Cremolini, Chiara
    INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (09) : 2652 - 2654
  • [26] High dose 5FU biomodulation by high dose leucovorin and individual 5FU dose adjustment in metastatic colorectal cancer. A multicentric prospective study of 130 patients
    Gamelin, E
    Delva, R
    Dumasnil, Y
    Jacob, J
    Maillart, P
    Calle, MB
    Goudier, MJ
    Lortholary, A
    Hardouin, A
    Geslin, J
    Hetroy, J
    Larra, F
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 729 - 729
  • [27] The role of levamisole (LEV) in the adjuvant treatment of stage III colon cancer (CC): A randomized trial of LEV and 5-fluorouracil (5FU) versus 5FU alone on behalf of "Colon Adiuvante Marche".
    Catalano, V
    Cascinu, S
    Silva, RR
    Mattioli, R
    Marcellini, M
    Pancotti, A
    Bascioni, R
    Torresi, U
    Catalano, G
    Cellerino, R
    ANNALS OF ONCOLOGY, 2000, 11 : 52 - 52
  • [28] Lymph node (LN) retrieval as a high-risk factor in stage II and III colon cancer
    Kim, Y. T.
    Kim, H. S.
    Shin, S. J.
    Beom, S-H.
    Kim, N. K.
    Lee, K. Y.
    Min, B. S.
    Hur, H.
    Cho, M. S.
    Han, Y. D.
    Yang, S. Y.
    Koom, W. S.
    Chang, J. S.
    Kim, T. I.
    Cheon, J. H.
    Park, S. J.
    Park, J. J.
    Seo, N. E.
    Lim, J. S.
    Ahn, J. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S418 - S419
  • [29] Colorectal cancer: Autologous immunogenicity in chemotherapy (5FU) pretreated patients.
    Lasalvia-Prisco, E
    Cucchi, S
    Vazquez, J
    Lasalvia-Galante, EL
    Golomar, W
    Cotto, F
    Otero, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 186S - 186S
  • [30] High-risk groups of patients with stage II colon carcinoma
    Merkel, S
    Wein, A
    Günther, K
    Papadopoulos, T
    Hohenberger, W
    Hermanek, P
    CANCER, 2001, 92 (06) : 1435 - 1443
12345